Revenue

6 Months Ended

Mar. 31, 2021

Revenue From Contract With Customer [Abstract]

Revenue

2. Revenue

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment.

	Three Months Ended				Six Months Ended
	March 31,				March 31,
(In thousands)	2021		2020		2021		2020
Medical Device
Product sales	$	5,410	$	5,455	$	9,971	$	10,477
Royalties		7,474		6,714		15,383		15,613
Research, development and other		2,445		2,628		4,746		4,862
License fees		12,578		1,507		14,003		2,756
Total Revenue — Medical Device		27,907		16,304		44,103		33,708
In Vitro Diagnostics
Product sales		6,373		6,315		11,914		11,267
Research, development and other		715		203		1,275		463
Total Revenue — In Vitro Diagnostics		7,088		6,518		13,189		11,730
Total Revenue	$	34,995	$	22,822	$	57,292	$	45,438

Contract assets totaled $6.6 million and $6.1 million as of March 31, 2021 and September 30, 2020, respectively. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 3 Collaborative Arrangements.